Drug Trial Radar · NCT04372108
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,536
Planned (sponsor's estimate)
Start
Jun 24, 2021
Primary completion
Aug 31, 2029
Study completion Aug 30, 2030
Sponsor
- Lead sponsor
- Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 1, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
Conditions
- Crohn Disease
- Colitis, Ulcerative
Interventions
UstekinumabDrug
Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
Other Biologic TherapiesDrug
Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rate for MalignancyTime frame: Up to 10 years and 3 months
- Time from Treatment Initiation to First Diagnosed MalignancyTime frame: Up to 10 years and 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
BAMC
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.